Jennifer M. Giltnane, M.D., Ph.D
Division of Investigative Pathology
Dept. of Pathology, Microbiology and Immunology
- Clinical Trials Information
- Clinical Trials: 1-800-811-8480
- Online Self-Referral Form
- Other Telephone NumbersVanderbilt University Medical Center
- FaxesOffice Fax
Vanderbilt University Medical Center
1211 Medical Center Drive
Nashville, TN 37232
2220 Pierce Avenue
649 Preston Research Building
Nashville, TN 37232
Dr. Giltnane is a junior faculty breast and molecular pathologist with a special interest in diagnostic quality improvement for the management and treatment of breast disease. She has research expertise in the development genomic and proteomic biomarkers for diagnosis, prediction, and prognosis in breast cancer as well as clinical expertise in the processing of tissue specimens and biobanking.
Read more ....
Dr. Giltnane is a junior faculty breast and molecular pathologist with a special interest in diagnostic quality improvement for the management and treatment of breast disease. She has research expertise in the development genomic and proteomic biomarkers for diagnosis, prediction, and prognosis in breast cancer as well as clinical expertise in the processing of tissue specimens and biobanking. She is currently supported by the Department of Pathology, Microbiology, and Immunology to pursue post-doctoral training in the laboratory of Carlos Artega, M.D., focused on translational research technologies including next-generation sequencing toward the improvement of outcomes in breast cancer.
- MD, Yale University School of Medicine, 2008
- PhD, Yale University Graduate School of Arts, 2008
- Residency, Anatomic and Clinical Pathology, Vanderbilt University Medical Center, 2012
I am continuing my career at Vanderbilt with a focus on biomarker discovery and validation for the prediction of treatment resistance and recurrence in breast cancer. Currently, I am exploring the mechanisms of resistance to endocrine therapy utilizing tissue from a presurgical tissue trial of aromatase inhibitor treatment in operable ER+ breast cancers. Through multi-platform molecular profiling of these tumors, I hope to identify actionable somatic alterations and uncover additional therapeutic liabilities to overcome treatment resistance. A long-term goal is to develop a cost-effective, protein-based biomarker assay to predict endocrine-response in ER+ breast cancer, informed by my experience with quantitative protein measurements in tissue.
Second, in a collaborative project currently funded by a DOD Breast Cancer Research Program Breakthrough Award, I am determining the incidence and impact of JAK2 alterations in triple negative breast cancer. My research partner discovered JAK2 amplification in residual tumors after neoadjuvant chemotherapy. We have evidence that clonal populations in primary tumors containing this change are selected by treatment pressure, leading to a more aggressive tumor profile.
Finally, in an effort funded by the Patient-Centered Outcomes Research Institute (PCORI), I am working to establish an institution-wide pathological sample biorepository (PathLink), which will be linked to the local medical record databases, the Research (RD, identified) and Synthetic Derivatives (SD, deidentified). Our initial objective is to seed this research resource with ¿¿¿on the shelf¿¿¿ remnant DNA samples and tissues. Initial efforts will be focused on tumor samples highly annotated in the medical record, a subset of which has been profiled already in the molecular genetic pathology laboratory. These specimens are invaluable resource to my own research, and also to the research community, but only if they are quickly accessible to the investigators that need them. We are proposing a system that will allow banking of these specimens while also preserving tissue for future clinical assays if necessary.
Biobanking and tissue management for clinical studies, tissue microarray studies of clinical trial cohorts
- Jeselsohn, R, Yelensky, R, Buchwalter, G, Frampton, G, Meric-Bernstam, F, Gonzalez-Angulo, AM, Ferrer-Lozano, J, Perez-Fidalgo, JA, Cristofanilli, M, G¿¿mez, H, Arteaga, CL, Giltnane, J, Balko, JM, Cronin, MT, Jarosz, M, Sun, J, Hawryluk, M, Lipson, D, Otto, G, Ross, JS, Dvir, A, Soussan-Gutman, L, Wolf, I, Rubinek, T, Gilmore, L, Schnitt, S, Come, SE, Pusztai, L, Stephens, P, Brown, M, Miller, VA Emergence of constitutively active estrogen receptor-¿¿ mutations in pretreated advanced estrogen receptor-positive breast cancer. Clin Cancer Res, 20(7), 1757-67, 2014.
- Owens, P, Pickup, MW, Novitskiy, SV, Giltnane, JM, Gorska, AE, Hopkins, CR, Hong, CC, Moses, HL Inhibition of BMP signaling suppresses metastasis in mammary cancer. Oncogene, 2014.
- Balko, JM, Giltnane, JM, Wang, K, Schwarz, LJ, Young, CD, Cook, RS, Owens, P, Sanders, ME, Kuba, MG, S¿¿nchez, V, Kurupi, R, Moore, PD, Pinto, JA, Doimi, FD, G¿¿mez, H, Horiuchi, D, Goga, A, Lehmann, BD, Bauer, JA, Pietenpol, JA, Ross, JS, Palmer, GA, Yelensky, R, Cronin, M, Miller, VA, Stephens, PJ, Arteaga, CL Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. Cancer Discov, 4(2), 232-45, 2014.
- Ondrejka, SL, Jegalian, AG, Kim, AS, Chabot-Richards, DS, Giltnane, J, Czuchlewski, DR, Shetty, S, Sekeres, MA, Yenamandra, A, Head, D, Jagasia, M, Hsi, ED PDGFRB-rearranged T-lymphoblastic leukemia/lymphoma occurring with myeloid neoplasms: The missing link supporting a stem cell origin. Haematologica, 2014.
- Giltnane, JM, Balko, JM Rationale for targeting the Ras/MAPK pathway in triple-negative breast cancer. Discov Med, 17(95), 275-83, 2014.
- Chmielecki, J, Peifer, M, Viale, A, Hutchinson, K, Giltnane, J, Socci, ND, Hollis, CJ, Dean, RS, Yenamandra, A, Jagasia, M, Kim, AS, DavÃ©, UP, Thomas, RK, Pao, W Systematic screen for tyrosine kinase rearrangements identifies a novel C6orf204-PDGFRB fusion in a patient with recurrent T-ALL and an associated myeloproliferative neoplasm. Genes Chromosomes Cancer, 51(1), 54-65, 2012.
- Anagnostou, VK, Welsh, AW, Giltnane, JM, Siddiqui, S, Liceaga, C, Gustavson, M, Syrigos, KN, Reiter, JL, Rimm, DL Analytic variability in immunohistochemistry biomarker studies. Cancer Epidemiol Biomarkers Prev, 19(4), 982-91, 2010.
- Rokicki, J, Das, PM, Giltnane, JM, Wansbury, O, Rimm, DL, Howard, BA, Jones, FE The ERalpha coactivator, HER4/4ICD, regulates progesterone receptor expression in normal and malignant breast epithelium. Mol Cancer, 9150, 2010.
- Giltnane, JM, Moeder, CB, Camp, RL, Rimm, DL Quantitative multiplexed analysis of ErbB family coexpression for primary breast cancer prognosis in a large retrospective cohort. Cancer, 115(11), 2400-9, 2009.
- Moeder, CB, Giltnane, JM, Moulis, SP, Rimm, DL Quantitative, fluorescence-based in-situ assessment of protein expression. Methods Mol Biol, 520163-75, 2009.
- Giltnane, JM, Molinaro, A, Cheng, H, Robinson, A, Turbin, D, Gelmon, K, Huntsman, D, Rimm, DL Comparison of quantitative immunofluorescence with conventional methods for HER2/neu testing with respect to response to trastuzumab therapy in metastatic breast cancer. Arch Pathol Lab Med, 132(10), 1635-47, 2008.
- Rimm, DL, Giltnane, JM, Moeder, C, Harigopal, M, Chung, GG, Camp, RL, Burtness, B Bimodal population or pathologist artifact (Letter to the editor). J Clin Oncol, 25(17), 2487-8, 2007.
- *Moeder, CB, *Giltnane, JM, Harigopal, M, Molinaro, A, Robinson, A, Gelmon, K, Huntsman, D, Camp, RL, Rimm, DL. *Authors contributed equally Quantitative justification of the change from 10% to 30% for human epidermal growth factor receptor 2 scoring in the American Society of Clinical Oncology/College of American Pathologists guidelines: tumor heterogeneity in breast cancer and its implications for tissue microarray based assessment of outcome. J Clin Oncol, 25(34), 5418-25, 2007.
- Giltnane, JM, RydÃ©n, L, Cregger, M, Bendahl, PO, JirstrÃ¶m, K, Rimm, DL Quantitative measurement of epidermal growth factor receptor is a negative predictive factor for tamoxifen response in hormone receptor positive premenopausal breast cancer. J Clin Oncol, 25(21), 3007-14, 2007.
- Giltnane, JM, Murren, JR, Rimm, DL, King, BL AQUA and FISH analysis of HER-2/neu expression and amplification in a small cell lung carcinoma tissue microarray. Histopathology, 49(2), 161-9, 2006.
- Dolled-Filhart, M, McCabe, A, Giltnane, J, Cregger, M, Camp, RL, Rimm, DL Quantitative in situ analysis of beta-catenin expression in breast cancer shows decreased expression is associated with poor outcome. Cancer Res, 66(10), 5487-94, 2006.
- Giltnane, JM, Rimm, DL Technology insight: Identification of biomarkers with tissue microarray technology. Nat Clin Pract Oncol, 1(2), 104-11, 2004.
- Rosenwald, A, Wright, G, Wiestner, A, Chan, WC, Connors, JM, Campo, E, Gascoyne, RD, Grogan, TM, Muller-Hermelink, HK, Smeland, EB, Chiorazzi, M, Giltnane, JM, Hurt, EM, Zhao, H, Averett, L, Henrickson, S, Yang, L, Powell, J, Wilson, WH, Jaffe, ES, Simon, R, Klausner, RD, Montserrat, E, Bosch, F, Greiner, TC, Weisenburger, DD, Sanger, WG, Dave, BJ, Lynch, JC, Vose, J, Armitage, JO, Fisher, RI, Miller, TP, LeBlanc, M, Ott, G, Kvaloy, S, Holte, H, Delabie, J, Staudt, LM The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell, 3(2), 185-97, 2003.
- Shaffer, AL, Lin, KI, Kuo, TC, Yu, X, Hurt, EM, Rosenwald, A, Giltnane, JM, Yang, L, Zhao, H, Calame, K, Staudt, LM Blimp-1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program. Immunity, 17(1), 51-62, 2002.
- Rosenwald, A, Wright, G, Chan, WC, Connors, JM, Campo, E, Fisher, RI, Gascoyne, RD, Muller-Hermelink, HK, Smeland, EB, Giltnane, JM, Hurt, EM, Zhao, H, Averett, L, Yang, L, Wilson, WH, Jaffe, ES, Simon, R, Klausner, RD, Powell, J, Duffey, PL, Longo, DL, Greiner, TC, Weisenburger, DD, Sanger, WG, Dave, BJ, Lynch, JC, Vose, J, Armitage, JO, Montserrat, E, LÃ³pez-Guillermo, A, Grogan, TM, Miller, TP, LeBlanc, M, Ott, G, Kvaloy, S, Delabie, J, Holte, H, Krajci, P, Stokke, T, Staudt, LM, , The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med, 346(25), 1937-47, 2002.